Viewing Study NCT06143956


Ignite Creation Date: 2025-12-24 @ 11:37 PM
Ignite Modification Date: 2025-12-28 @ 6:24 PM
Study NCT ID: NCT06143956
Status: RECRUITING
Last Update Posted: 2025-12-23
First Post: 2023-11-06
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Sponsor: Eli Lilly and Company
Organization:

Study Overview

Official Title: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Interventions for Chronic Weight Management in Adult Participants With Obesity or Overweight
Status: RECRUITING
Status Verified Date: 2025-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA's complete.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
W8M-MC-CWMM OTHER Eli Lilly and Company View
W8M-MC-OXA1 OTHER Eli Lilly and Company View
W8M-MC-LAA1 OTHER Eli Lilly and Company View
W8M-MC-LAA2 OTHER Eli Lilly and Company View
W8M-MC-GN01 OTHER Eli Lilly and Company View
W8M-MC-GN02 OTHER Eli Lilly and Company View